Condition: MSS Metastatic Colorectal Cancers · MSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy · Sponsor: Peking University Cancer Hospital & Institute
This study is a single-center prospective exploratory research, aiming to identify clinical characteristics and biomarkers associated with the therapeutic effects of dual PD1/PDL1 and CTLA4 blockade plus anti-angiogenic therapy and investigate MR image characteristics during treatment in patients with MSS metastatic colorectal cancer and MSI solid tumors resistant to PD-1/PD-L1 antibody monotherapy.
This description comes directly from the study's public registry record.
Zhenghang Wang · 18813186790 · zhenghang_wang@bjmu.edu.cn
Ting Xu
Always discuss trial participation with your own doctor first.
| Jian Li | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06549907